Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.
Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A.
Pugliese D, et al.
Expert Opin Biol Ther. 2021 Jan;21(1):97-104. doi: 10.1080/14712598.2020.1839045. Epub 2020 Oct 31.
Expert Opin Biol Ther. 2021.
PMID: 33074723